Lulizumab pegol

DB15441Investigational

Lulizumab pegol is under investigation in clinical trial NCT02843659 (Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome).

Mechanism: Pharmacologically active on T-cell-specific surface glycoprotein CD28
Curator reviewed
Also known as: BMS-931699

Resolves to

Compound

UNIILCT264LTYECAS1421830-13-8

Targets

P10747CD28

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

381Drug interactionsStructured to mechanism, not free text

5Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lulizumab pegol, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account